The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy

PURPOSE: To develop a novel criterion based on the response evaluation criteria in solid tumors (RECIST) 1.1 and alpha fetoprotein (AFP) and evaluate its performance in tumor response for patients with unresectable hepatocellular carcinoma (uHCC) receiving conversion-radiotherapy before hepatectomy....

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ying, Yang, Yi, Li, Lu, Ye, Feng, Zhao, Xinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170883/
https://www.ncbi.nlm.nih.gov/pubmed/35686094
http://dx.doi.org/10.3389/fonc.2022.905260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170883/
https://www.ncbi.nlm.nih.gov/pubmed/35686094
http://dx.doi.org/10.3389/fonc.2022.905260

Ejemplares similares